SAR446422
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 02, 2024
A randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of SAR446422 in healthy, adult participants
(ANZCTR)
- P1 | N=120 | Suspended | Sponsor: Sanofi-Aventis Australia Pty Ltd | Recruiting ➔ Suspended
Trial suspension • Immunology
January 19, 2024
A randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of SAR446422 in healthy, adult participants
(ANZCTR)
- P1 | N=120 | Recruiting | Sponsor: Sanofi-Aventis Australia Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2023
Enrollment open • Trial initiation date • Immunology
1 to 2
Of
2
Go to page
1